ArticleTherapeutic advances in neurological disorders2024
Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.
Article in Therapeutic advances in neurological disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of efgartigimod as an effective treatment for myasthenic crisis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support.Journal of neuromuscular diseases · 2026Article
- Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod.BMC neurology · 2026Article
- Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety.Therapeutic advances in neurological disorders · 2026Article
- Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review.Neurology international · 2025Review
- Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.CNS neuroscience & therapeutics · 2025Article
- FcRn inhibitors for myasthenia gravis.The Cochrane database of systematic reviews · 2025Article
- Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series.Journal of inflammation research · 2025Article
- Case Report: A myasthenia gravis patient complicated with renal failure was effectively treated with efgartigimod.Frontiers in immunology · 2025Article
- Add-on efgartigimod in myasthenic crisis: a promising treatment option.Frontiers in neurology · 2025Article
- Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.Scientific reports · 2024Article
- Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report.BMC neurology · 2024Article
- First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report.Therapeutic advances in neurological disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis. Plasma exchange or intravenous immunoglobulin (IVIg) is the first-line treatment option for myasthenia crisis, but some patients still poorly respond to them. Here, we first reported a generalized MG patient from China who was in a state of impending myasthenic crisis and did not respond effectively to IVIg but was successfully rescued by add-on efgartigimod. Especially, we also detected meaningful changes in T-cell and B-cell subsets after efgartigimod, promoting a potential role of efgartigimod in re-establishing immune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.